Asian Penny Stocks To Watch In April 2025

In This Article:

As global markets grapple with economic uncertainty and inflation fears, Asian stock markets have shown resilience amid these challenges. For investors interested in smaller or newer companies, penny stocks—though an outdated term—still represent a compelling investment area. By focusing on those with strong balance sheets and solid fundamentals, investors can uncover potential growth opportunities at lower price points.

Top 10 Penny Stocks In Asia

Name

Share Price

Market Cap

Financial Health Rating

Interlink Telecom (SET:ITEL)

THB1.37

THB1.9B

★★★★☆☆

Chumporn Palm Oil Industry (SET:CPI)

THB2.74

THB1.73B

★★★★★★

CNMC Goldmine Holdings (Catalist:5TP)

SGD0.355

SGD143.88M

★★★★★☆

Beng Kuang Marine (SGX:BEZ)

SGD0.205

SGD40.84M

★★★★★★

Yangzijiang Shipbuilding (Holdings) (SGX:BS6)

SGD2.32

SGD9.17B

★★★★★☆

YesAsia Holdings (SEHK:2209)

HK$3.09

HK$1.27B

★★★★★★

Bosideng International Holdings (SEHK:3998)

HK$4.01

HK$45.93B

★★★★★★

Lever Style (SEHK:1346)

HK$1.39

HK$877.02M

★★★★★★

Goodbaby International Holdings (SEHK:1086)

HK$1.32

HK$2.2B

★★★★★★

Xiamen Hexing Packaging Printing (SZSE:002228)

CN¥3.14

CN¥3.64B

★★★★★★

Click here to see the full list of 1,115 stocks from our Asian Penny Stocks screener.

Let's review some notable picks from our screened stocks.

LifeTech Scientific

Simply Wall St Financial Health Rating: ★★★★★★

Overview: LifeTech Scientific Corporation is an investment holding company that develops, manufactures, and trades interventional medical devices for cardiovascular and peripheral vascular diseases globally, with a market cap of approximately HK$7.55 billion.

Operations: No specific revenue segments are reported for this company.

Market Cap: HK$7.55B

LifeTech Scientific has demonstrated financial stability with short-term assets of CN¥2.3 billion exceeding both its short and long-term liabilities, while maintaining a debt-free status. However, despite high-quality earnings, the company experienced negative earnings growth last year with net profit margins declining from 20.8% to 17.1%. Recent product developments include the LAmbre TM Plus Left Atrial Appendage Closure System's US trial and Ankura Aortic Stent Graft System's approval in China, indicating strategic advancements in medical device offerings that may enhance future revenue streams amidst current profitability challenges.

SEHK:1302 Financial Position Analysis as at Apr 2025
SEHK:1302 Financial Position Analysis as at Apr 2025

Tian Tu Capital

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Tian Tu Capital Co., Ltd. is a private equity and venture capital firm focusing on investments in small and medium-sized companies across various development stages, with a market cap of HK$2.53 billion.